Organisation paid for research Program year 2025 Source: CMS Open Payments

CB Flock Research Corporation

Neither a doctor nor a teaching hospital

Research payments

$1,946,638

291 payments

Through program year 2025, CB Flock Research Corporation is reported as receiving $1,946,638 in research payments, across 291 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$105,425	6
2024	Research	$111,243	20
2023	Research	$159,613	19
2022	Research	$304,900	37
2021	Research	$308,799	55
2020	Research	$419,339	78
2019	Research	$537,319	76

Breakdown

Who paid Research payments · program years 2019–2025

AbbVie, Inc. $1,556,462 248 payments
Novartis Pharmaceuticals Corporation $162,795 4 payments
Amgen Inc. $77,257 11 payments
Regeneron Pharmaceuticals, Inc. $70,139 21 payments
AstraZeneca UK Limited $56,416 4 payments
AstraZeneca Pharmaceuticals LP $22,568 2 payments
Array BioPharma Inc. $1,000 1 payment

Studies the money was for Research payments · program years 2019–2025

M16-100 $264,887 24 payments
M14-675 $216,632 20 payments
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) $208,838 28 payments
An Open-Label Extension Trial of the Phase III Lipid-Lowering Trials to Assess the Effect of Long Term Dosing of Inclisiran Given As Subcutaneous Injections in Subjects With High Cardiovascular Risk and Elevated LDL-C $162,795 4 payments
M14-430 $100,909 20 payments
M14-234 $93,784 23 payments
A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction Persistent Inflammation and Elevated N terminal Prohormone Brain Natriuretic Peptide $78,984 6 payments
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $78,914 12 payments
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis $68,149 11 payments
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 $63,423 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.